ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 82 filers reported holding ARBUTUS BIOPHARMA CORP in Q4 2020. The put-call ratio across all filers is 1.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $709,197 | -8.3% | 349,358 | +4.0% | 0.00% | – |
| Q2 2023 | $772,968 | -17.4% | 336,073 | +8.8% | 0.00% | – |
| Q1 2023 | $936,176 | +31.6% | 308,969 | +1.2% | 0.00% | – |
| Q4 2022 | $711,302 | +29.6% | 305,280 | +6.2% | 0.00% | – |
| Q3 2022 | $549,000 | -29.7% | 287,419 | -0.2% | 0.00% | – |
| Q2 2022 | $781,000 | +9.2% | 287,954 | +20.1% | 0.00% | – |
| Q1 2022 | $715,000 | -12.3% | 239,713 | +14.5% | 0.00% | – |
| Q4 2021 | $815,000 | -9.3% | 209,375 | 0.0% | 0.00% | – |
| Q3 2021 | $899,000 | +59.1% | 209,375 | +12.3% | 0.00% | – |
| Q2 2021 | $565,000 | +707.1% | 186,468 | +791.7% | 0.00% | – |
| Q1 2021 | $70,000 | -6.7% | 20,912 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -27.9% | 20,912 | -36.5% | 0.00% | – |
| Q3 2020 | $104,000 | -55.9% | 32,912 | -50.1% | 0.00% | – |
| Q1 2019 | $236,000 | -6.7% | 65,900 | 0.0% | 0.00% | – |
| Q4 2018 | $253,000 | -59.4% | 65,900 | 0.0% | 0.00% | – |
| Q3 2018 | $623,000 | +29.3% | 65,900 | 0.0% | 0.00% | – |
| Q2 2018 | $482,000 | – | 65,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 260,000 | $866,000 | 0.34% |
| RTW INVESTMENTS, LP | 5,978,355 | $19,908,000 | 0.31% |
| GSA CAPITAL PARTNERS LLP | 309,839 | $1,032,000 | 0.17% |
| QCM Cayman, Ltd. | 12,728 | $42,000 | 0.13% |
| COWEN AND COMPANY, LLC | 486,717 | $1,621,000 | 0.11% |
| Hudson Bay Capital Management LP | 1,400,000 | $4,662,000 | 0.06% |
| Kerrisdale Advisers, LLC | 208,150 | $693,000 | 0.05% |
| Secure Asset Management, LLC | 10,000 | $33,000 | 0.02% |
| PDT Partners, LLC | 72,500 | $241,000 | 0.02% |
| Point72 Asset Management, L.P. | 1,037,700 | $3,456,000 | 0.02% |